Table II.
Clinical characteristics and MI distribution of patients with NSCLC with a median age of 56 (range, 32–78).
| MI | ||||
|---|---|---|---|---|
| Clinicopathological characteristics | Case (%) | M | N | P-value |
| Sex | 0.96 | |||
| Male | 14 (43.8) | 3 | 11 | |
| Female | 18 (56.3) | 4 | 14 | |
| Smoking status | 0.98 | |||
| Smoker | 9 (28.1) | 5 | 18 | |
| Non-smoker | 23 (71.9) | 2 | 7 | |
| PS | 0.96 | |||
| 1 | 18 (56.3) | 4 | 14 | |
| 2 | 14 (43.8) | 3 | 11 | |
| Histological cell type | 0.80a | |||
| Adenocarcinoma | 24 (75) | 5 | 19 | |
| Squamous cell | 3 (9.4) | 1 | 2 | |
| Adenosquamocarcinoma | 2 (6.3) | 0 | 2 | |
| Othersb | 3 (9.4) | 1 | 2 | |
| EGFR status | 0.23c | |||
| Wild type | 9 (28.1) | 3 | 6 | |
| 19Del | 12 (37.5) | 6 | 6 | |
| L858R | 9 (28.1) | 6 | 3 | |
| Others | 2 (6.3) | 1 | 1 | |
a
Adenocarcinoma vs. non-adenocarcinoma
b
NSCLC-NOS (not otherwise specified) and large cell carcinoma
c
EGFR wild type vs. EGFR mutant. MI, methylation index; PS, performance status; NSCLC, non-small cell lung carcinoma; EGFR, epidermal growth factor receptor; M, methylated; N, non-methylated.